Neurosarcoïdose : caractéristiques cliniques et paracliniques des atteintes du système nerveux central

Par : Dos Santos, Amélie

Document archivé le : 15/12/2020 00:00

Neurological localizations of central nervous system are heterogenous and rare. Our main objective is to describe the clinical, biological and MRI pattern of this population. We retrospectively included 118 patients : 38 with isolated neurosarcoidosis (NS), 80 with NS associated with systemic sarcoidosis. The NS is the initial presentation in 77,9% of patients, with cranial nerves involvement (36,4%), medullary symptoms (22,8%) and seizures (21,2%). Patients were knowed to have systemic sarcoidosis in 20,6%. The diagnosis was concomittant of NS in 48,2% and post-NS in 52,8%. The ECA are increased in only 20,7%. The meningitis are present in 44,6% and hyperproteinorachia are frequent (69,5%). MRI results showed white matters abnormalities. The most useful treatment of NS is corticosteroids. Immunosupressive drugs are used in steroids resistant patients and to limit side-effects. Methotrexate and cyclophosphamid are frequently used with a good efficacy. Some study will be necessary to confirm efficacy and safety of anti-TNFa. 20 NANT 179M